App-Quantinova.ai

366 Abstracts

Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from cohort 17 of the COSMIC-021 study

Sylvie Rottey - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Cabozantinib

Multiple combinational strategies of immunotherapy for urothelial carcinoma in one institution

Jo-Pai Chen - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

A UNIQUE CASE OF CHOREIFORM DYSKINESIAS IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA

Ali-Musa Jaffer - Society for Neuro-Oncology (SNO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Metastatic Renal Cell Cancer

Cabozantinib

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study

D. Li - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Cabozantinib

Strategies for Alleviating Tyrosine Kinase Resistance in Acute Myeloid Leukemia By Modulating p53 Signaling Pathway with Small Molecules

Chi-Yang Tseng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cabozantinib

Transcriptomic-Based in silico Drug Screening Reveals Dual PI3K/mTOR Inhibitors Overcome Cabozantinib-Resistance of FLT3-ITD AML Cells

Chi-Yang Tseng - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cabozantinib

Filters

366 Abstracts